Page 139 - TD-3-4

Tumor Discovery CTC characterization for EGFR mutations

doi: 10.6004/jnccn.2023.0020 and monitoring using a combined analysis of the number
of Circulating Tumor Cells (CTCs) and other clinical
25. Lindeman NI, Cagle PT, Aisner DL, et al. Updated molecular parameters. Cancers (Basel). 2023;15(22):5372.
testing guideline for the selection of lung cancer patients
for treatment with targeted tyrosine kinase inhibitors: doi: 10.3390/cancers15225372
Guideline from the College of American Pathologists, the 35. Lawrence R, Watters M, Davies CR, Pantel K, Lu YJ.
International Association for the Study of Lung Cancer, and Circulating tumour cells for early detection of clinically
the Association for Molecular Pathology. Arch Pathol Lab relevant cancer. Nat Rev Clin Oncol. 2023;20(7):487-500.
Med. 2018;142:321-346.
doi: 10.1038/s41571-023-00781-y
doi: 10.5858/arpa.2017-0388-CP
36. Auwal A, Matakabbir Hassan M, Haque Prony TU, et al.
26. Martins I, Ribeiro IP, Jorge J, et al. Liquid biopsies: Clinical significance of genomic sequencing of Circulating
Applications for cancer diagnosis and monitoring. Genes Tumour Cells (CTCs) in cancer. J Liq Biopsy. 2024;3:100135.
(Basel). 2021;12(3):349.
doi: 10.1016/j.jlb;2023.100135
doi: 10.3390/genes12030349
37. Punnoose E, Atwal S, Liu W, et al. Evaluation of circulating
27. Kim MH, Kim SH, Lee MK, Eom JS. Recent advances in tumor cells and circulating tumor DNA in non-small cell
adjuvant therapy for non-small-cell lung cancer. Tuberc lung cancer: Association with clinical endpoints in a phase
Respir Dis (Seoul). 2024;87(1):31-39. II clinical trial of pertuzumab and erlotinib. Clin Cancer Res.
doi: 10.4046/trd.2023.0085 2012;18(8):2391-2401.
28. Malapelle U, Muscarella LA, Pisapia P, Rossi A. Targeting doi: 10.1158/1078-0432.CCR-11-3148
emerging molecular alterations in the treatment of non- 38. Sunderesan TK, Sequist LV, Haymach JV, et al. Detection
small cell lung cancer: Current challenges and the way of T790M, the acquired resistance EGFR mutation, by
forward. Expert Opin Investig Drugs. 2020;29(4):363-372. tumor biopsy versus noninvasive blood-based analyses. Clin
doi: 10.1080/13543784.2020.1732922 Cancer Res. 2016;22(5):1103-1110.
29. Jamal-Hanjani M, Wilson GA, McGranahan N, et al. doi: 10.1158/1078-0432ccr-15-1031
Tracking the evolution of non-small-cell lung cancer. N Engl 39. Keup C, Kimmig, R,Kasimir-Bauer S. Multimodality
J Med. 2017;376(22):2109-2121. in liquid biopsy: Does a combination uncover insights
doi: 10.1056/NEJMoa1616288 undetectable in individual blood analytes? J Lab Med.
2022;46(4):255-264.
30. Tan AC, Tan DSW. Targeted therapies for lung cancer
patients with oncogenic driver molecular alterations. J Clin doi: 10.1515/labmed-2022-0009
Oncol. 2022;40(6):611-625. 40. Nagrath S, Sequist L, Maheswaran S, et al. Isolation of rare
doi: 10.1200/JCO.21.01626 circulating tumour cells in cancer patients by microchip
technology. Nature. 2007;450(7173):1235-1239.
31. Thress KS, Brant R, Carr TH, et al. EGFR mutation detection
in ctDNA from NSCLC patient plasma: A cross-platform doi: 10.1038/nature06385
comparison of leading technologies to support the clinical 41. Rushton A, Nteliopoulos G, Shaw J, Coombes RS. A review
development of AZD9291. Lung Cancer. 2015;90(3):509-515. of circulating tumour cell enrichment technologies. Cancers
doi: 10.1016/j.lungcan.2015.10.004 (Basel). 2021;13(5):970.
32. Roldan Ruiz J, Fuentes Gago MG, Chinchilla Tabora LM, doi: 10.3390/cancers13050970
et al. The impact of liquid biopsies positive for EGFR 42. Habili Z, Al chama W, Saab R, Kadara H, Kharaiche ML.
mutations on overall survival in non-small cell lung cancer Circulatory tumour cell detection technologies and clinical
patients. Diagnostics (Basel). 2023;13(14):2347. utility: Challenges and opportunities. Cancers (Basel).
doi: 10.3390/diagnostics13142347 2020;12(7):1930.
33. Rossi E, Aieta M, Tartarone A, et al. A fully automated assay doi: 10.3390/cancers12071930
to detect the expression of pan-cytokeratins and of EML4- 43. Ring A, Nguyen-Sträuli BD, Wicki A, Aceto N. Biology,
ALK fusion protein in circulating tumour cells (CTCs) vulnerabilities and clinical applications of circulating
predicts outcome of non-small cell lung cancer (NSCLC) tumour cells. Nat Rev Cancer. 2023;23:95-111.
patients. Transl Lung Cancer Res. 2021;10(1):80-92.
doi: 10.1038/s41568-022-00536-4
doi: 10.21037/tlcr-20-855
44. Tran HH, Wu W, Lee NY. Ethanol and UV-assisted
34. Nguyen TNA, Huang PS, Chu PY, Hseih CH, Wu MH. instantaneous bonding of PMMA assemblies and tuning in
Recent progress in enhanced cancer diagnosis, prognosis, bonding reversibility. Sens Actuators B Chem. 2013;181:955-962.

Volume 3 Issue 4 (2024) 15 doi: 10.36922/td.3987